Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-WN-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
LENTI-WN-01 is a preclinical-stage, non-integrative lentiviral vector-based vaccine candidate developed by Theravectys for the prevention of West Nile virus (WNV) infection. The vaccine utilizes Theravectys's proprietary lentiviral vector platform to deliver genetic material encoding a secreted form of the West Nile virus envelope (E) glycoprotein. By targeting non-dividing dendritic cells, the vaccine stimulates a robust and long-lasting immune response, including both humoral (neutralizing antibodies) and cellular (T-cell) immunity, without integrating into the host genome.
- Other names
- West Nile Virus Vaccine (Theravectys)
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on LENTI-WN-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-WN-01.